Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

190.40 -2.07 (-1.08%)
Official Closing Price Updated: 7:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
The company is looking to take on Bristol Myers Squibb's Sotyktu in plaque psoriasis treatment. 
Via Investor's Business Daily
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
3 Dividend Kings Shaking Off Market Woes
The market has thrown a tantrum over recent weeks following tariff news and other economic data pointing to a slowing consumer base. While it’s certainly been a turbulent period, several stocks have... 
Via Talk Markets
Topics Stocks / Equities World Trade
Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'
Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion 
Via Benzinga
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug
HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025. 
Via Benzinga
What 14 Analyst Ratings Have To Say About Johnson & Johnson
 
Via Benzinga
What the Options Market Tells Us About Johnson & Johnson
 
Via Benzinga
A Closer Look at Johnson & Johnson's Options Market Dynamics
 
Via Benzinga
Broaden Your ETF Exposure With These 3 Overlooked Funds
These ETFs have outperformed the market so far in 2025 but have lower asset bases than some of the most popular funds among investors. 
Via MarketBeat
Topics ETFs Economy Government
2 Dow Stocks to Buy Hand Over Fist in March and 1 to Avoid
Two of the Dow Jones Industrial Average's 30 components make for no-brainer buys, while another brand-name member continues to suffer from self-inflicted wounds. 
Via The Motley Fool
Topics Stocks
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations
From Johnson & Johnson
Via Business Wire
Tech Sector Hammered As Trump's Tariff Plans Spark Market Selloff: Nvidia, ARM, Super Micro Lead Tech Bloodbath
U.S. markets suffered a steep selloff Monday as President Donald Trump announced sweeping new tariffs, extending last week's losses and driving declines across all major sectors. 
Via Benzinga
Topics Government World Trade
Warren Buffett's State of the Market
Berkshire's cash hoard is approaching "Dr. Evil" levels. 
Via The Motley Fool
These Vanguard ETFs Show Where the Smart Money Is Moving Now
Via The Motley Fool
Topics ETFs
3 Top High-Yield Dividend Stocks I Plan to Buy in March for More Passive Income
Via The Motley Fool
3 Dividend Stocks That Are No-Brainer Buys Right Now
Via The Motley Fool
Bitcoin, Magnificent 7 Lose Safe-Haven Status In 2025 As China ETFs, Dow Stocks Outperform
Many of the top-performing stocks and assets in recent years have stumbled at the start of 2025, with Bitcoin (CRYPTO: BTC) dropping to a three-month low. 
Via Benzinga
Topics ETFs Stocks
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang
LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts. 
Via Benzinga
Wall Street's Greatest Dividend Stock Just Made History Again -- and 99.9% of Investors Have Never Heard of This Small-Cap Company
This virtually unknown company has been paying a continuous dividend for six decades longer than any other U.S. stock. 
Via The Motley Fool
Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026. 
Via Benzinga
Johnson & Johnson Sues Samsung Bioepis Over Alleged Biosimilar Agreement Breach For Its Flagship Psoriasis Drug
Janssen has sued Samsung Bioepis, alleging it violated a settlement agreement by authorizing an unauthorized Stelara® biosimilar, potentially harming market competition. 
Via Benzinga
Topics Lawsuit
3 Dividend-Paying Stocks Bucking the Market’s Trend
Via MarketBeat
Biotech Stocks Stay Strong Through A Period Of Uncertainty In The Market
Many analysts are feeling better about the prospects for healthcare stocks in 2025. 
Via Talk Markets
Topics ETFs Stocks / Equities
2 Very Healthy High-Yield Dividend Stocks to Buy for a Safe and Growing Passive Income Stream
Via The Motley Fool
Buy This Ultra-Safe High-Yield Dividend King Stock for Reliable Passive Income
Via The Motley Fool
NVIDIA's New AI System Aims To Transform Genetic Research With Unmatched Speed And Precision
NVIDIA (NASDAQ: NVDA) has introduced Evo 2, an advanced artificial intelligence (AI) system aimed at transforming the field of biological research. 
Via Benzinga
Topics Artificial Intelligence
Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports
Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors. 
Via Benzinga
Topics ETFs Government World Trade
Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst
Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025. 
Via Benzinga
Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich
Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion. 
Via Benzinga
Topics Government
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.